Resveratrol-induced apoptosis is enhanced in acute lymphoblastic leukemia cells by modulation of the mitochondrial permeability transition pore

Cancer Letters

Volumn 240, Issue 1, 2006, Pages 123-134

  Zunino, Susan J ^a   Storms, David H ^a  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

Apoptosis; Cyclosporin A; Leukemia; PK11195; Resveratrol

Indexed keywords

CYCLOSPORIN A; LIPOCORTIN 5; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; RESVERATROL;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ASSAY; CELL DEATH; CELL MEMBRANE DEPOLARIZATION; CHROMOSOME TRANSLOCATION 4; CONTROLLED STUDY; DRUG POTENTIATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKEMIA CELL LINE; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELLS, CULTURED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; ISOQUINOLINES; JURKAT CELLS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MEMBRANE POTENTIALS; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MITOCHONDRIAL MEMBRANES; STILBENES;

EID: 33745808321     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.09.001     Document Type: Article

References (41)

1. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W.W., Fong H.H.S., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., and Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997) 218-220
2. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., and Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24 (2004) 2783-2840
3. Zheng J., and Ramirez V.D. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase polyphenolic phytochemicals. Brit. J. Pharmacol. 130 (2000) 1115-1123
4. Dorrie J., Gerauer H., Wachter Y., and Zunino S.J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 61 (2001) 4731-4739
5. Tinhofer I., Bernhard D., Senfter M., Anether G., Loeffler M., Kroemer G., Kofler R., Csordas A., and Greil R. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J. 15 (2001) 1613-1615
6. Marchetti P., Castedo M., Susin S.A., Zamzami N., Hirsch T., Macho A., Haeffner A., Hirsch F., Geuskens M., and Kroemer G. Mitochondrial permeability transition is a central coordinating event of apoptosis. J. Exp. Med. 184 (1996) 1155-1160
7. Casellas P., Galiegue S., and Basile A.S. Peripheral benzodiazepine receptors and mitochondrial function. Neurochemistry International 40 (2002) 475-486
8. Faderl S., Kantarjian H.M., Talpaz M., and Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91 (1998) 3995-4019
9. Greaves M.F., and Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nature Rev. 3 (2003) 1-11
10. Crompton M., Ellinger H., and Costi A. Inhibition by cyclosporin A of a Ca2+-dependent pore in heart mitochondria activated by inorganic phosphate an oxidative stress. Biochem J. 255 (1988) 357-360
11. Connern C.P., and Halestrap A.P. Purification and N-terminal sequencing of peptidyl-prolyl cis-trans-isomerase from rat liver mitochondrial matrix reveals the existence of a distinct mitochondrial cyclophilin. Biochem J. 284 (1992) 381-385
12. Hirsch T., Decaudin D., Susin S.A., Marchetti P., Larochette N., Resche-Rigon M., and Kroemer G. PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection. Exp. Cell Res. 241 (1998) 426-434
13. Bustamante J., Caldas Lopes E., Garcia M., Di Libero E., Alvarez E., and Hajos S.E. Disruption of mitochondrial membrane potential during apoptosis induced by PSC833 and CsA in multidrug-resistant lymphoid leukemia. Toxicol. Appl. Pharmacol. 199 (2004) 44-51
14. Fennell D.A., Corbo M., Pallaska A., and Cotter F.E. Bcl-2 resistant mitochondrial toxicity mediated by the isoquinoline carboxamide PK11195 involved de novo generation of reactive oxygen species. Brit. J. Cancer 84 (2001) 1397-1404
15. Ito C., Ribeiro R.C., Behm F.G., Raimondi S.C., Pui C.-H., and Campana D. Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood 91 (1998) 1001-1007
16. Greil J., Gramatzki M., Burger R., Marschalek R., Peltner M., Trautman U., Hansen-Hagge T.E., Bartram C.R., Fey G.H., Stehr K., and Beck J. The acute lymphoblastic leukemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. Brit. J. Haematol. 86 (1994) 275-283
17. Strong R.C., Korsmeyer S.J., Parkin J.L., Arthur D.C., and Kersey J.H. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 65 (1985) 21-31
18. Dorrie J., Schuh W., Keil A., Bongards E., Greil J., Fey G.H., and Zunino S.J. Regulation of CD95 expression and CD95-mediated cell death by interferon-γ in acute lymphoblastic leukemia with chromosomal translocation t(4;11). Leukemia 13 (1999) 1539-1547
19. Martin J.S., Reutelingsperger C.P., McGahon A.J., Rader J.A., vanShie R.C., LaFace D.M., and Green D.R. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182 (1995) 1545-1556
20. Vermes I., Haanen C., Steffens-Nakkan H., and Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled annexin V. J. Immunol. Methods 184 (1995) 39-51
21. Cossarizza A., Kalashnikova G., Grassilli E., Chiappelli F., Salvioli S., Capri M., Barbieri D., Troiano L., Monti D., and Franceschi C. Mitochondrial modifications during rat thymocyte apoptosis: a study at the single cell level. Exp. Cell Res. 214 (1994) 323-330
22. List A.F., Kopecky K.J., Willman C.L., Head D.R., Persons D.L., Slovak M.L., Dorr R., Karanes C., Hynes H.E., Doroshow J.H., Shurafa M., and Appelbaum F.R. Benefits of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98 (2001) 3212-3220
23. Banker D.E., Cooper J.J., Fennell D.A., Willman C.L., Appelbaum F.R., and Cotter E. PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism. Leukemia Res. 26 (2002) 91-106
24. Homolya L., Hollo Z., Germann U.A., Pastan I., Gottesman M.M., and Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 268 (1993) 21493-21496
25. Lautier D., Canitrot Y., Deeley R.G., and Cole S.P.C. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem. Pharmacol. 52 (1996) 967-977
26. Fontecave M., Lepoivre M., Elleingand E., Gerez C., and Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 421 (1998) 277-279
27. Gautam S.C., Xu Y.X., Dumaguin M., Janakiraman N., and Chapman R.A. Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging. Bone Marrow Transpl. 25 (2000) 639-645
28. Vander Heiden M.G., and Thompson C.B. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis. Nat. Cell Biol. 1 (1999) 209-216
29. Marzo I., Brenner C., Zamzani N., Jurgensmeier J.M., Susin S.A., Vieira H.L.A., Prevost M.C., Xie Z., Matsuyama S., Reed J.C., and Kroemer G. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 281 (1998) 2027-2031
30. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J. 341 (1999) 233-249
31. Brenner C., Cadiou H., Vieira H.L.A., Zamzani N., Marzo I., Xie Z., Leber B., Andrews D., Duclohier H., Reed J.C., and Kroemer G. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene 19 (2000) 329-336
32. Bernardi P., Scorrano L., Colonna R., Petronilli V., and Di Lisa F. Mitochondria and cell death, mechanistic aspects and methodological issues. Eur. J. Biochem. 264 (1999) 687-701
33. Broekemeier K.M., and Pfeiffer D.R. Inhibition of the mitochondrial permeability transition by cyclosporine A during long time frame experiments: relationship between pore opening and the activity of mitochondrial phospholipases. Biochemistry 34 (1995) 16440-16449
34. Walter R.B., Raden B.W., Cronk M.R., Bernstein I.D., Appelbaum F.R., and Banker D.E. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood 103 (2004) 4276-4284
35. Karawajew L., Wuchter C., Ruppert V., Drexler H., Gruss H.J., Dorken B., and Ludwig W.D. Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Leukemia 11 (1997) 1245-1252
36. Dorrie J., Sapala K., and Zunino S.J. Interferon-γ increases the expression of glycosylated CD95 in B-leukemic cells: An inducible model to study the role of glycosylation in CD95-signaling and trafficking. Cytokine 18 (2002) 98-107
37. Ferry A., Jaillon P., Lecocq B., Lecocq V., and Jozefczak C. Pharmacokinetics and effects on exercise heart rate of PK11195 (52028 RP), an antagonist of peripheral benzodiazepine receptors, in healthy volunteers. Fundam. Clin. Pharmacol. 3 (1989) 383-392
38. Ansseau M., von Frenckell R., Cerfontaine J.L., and Papart P. Pilot study of PK11195, a selective ligand for the peripheral-type benzodiazepine binding sites, in inpatients with anxious or depressive symptomatology. Pharmacopsychiatry 24 (1991) 8-12
39. Bauer K.S., Karp J.E., Garimella T.S., Wu S., Tan M., and Ross D.D. A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. Leukemia Res. 29 (2005) 263-271
40. Liem N.L.M., Papa R.A., Milross C.G., Schmid M.A., Tajbakhsh M., Choi S., Ramirez C.D., Rice A.M., Haber M., Norris M.D., MacKenzie K.L., and Lock R.B. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 103 (2004) 3905-3914
41. Lock R.B., Liem N., Farnsworth M.L., Milross C.G., Xue C., Tajbakhsh M., Haber M., Norris M.D., Marshall G.M., and Rice A.M. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 99 (2002) 4100-4108